A rating of 75 puts Kiniksa Pharmaceuticals Ltd (KNSA) near the top of the Biotechnology industry according to InvestorsObserver. Kiniksa Pharmaceuticals Ltd's score of 75 means it scores higher than 75% of stocks in the industry. Kiniksa Pharmaceuticals Ltd also received an overall rating of 63, putting it above 63% of all stocks. Biotechnology is ranked 15 out of the 148 industries.
What do These Ratings Mean?
Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.
What's Happening With Kiniksa Pharmaceuticals Ltd Stock Today?
Kiniksa Pharmaceuticals Ltd (KNSA) stock has gained 4.84% while the S&P 500 has fallen -0.65% as of 10:05 AM on Thursday, Feb 18. KNSA is higher by $1.09 from the previous closing price of $22.52 on volume of 82,129 shares. Over the past year the S&P 500 has risen 15.34% while KNSA is higher by 29.30%. KNSA lost -$2.37 per share the over the last 12 months.